The Stable expression subtype encompasses algal lines in which the recombinant gene is permanently integrated into the nuclear or chloroplast genome, enabling continuous protein production over multiple harvest cycles. Generation of stable transformants typically involves homologous recombination, particle bombardment, or CRISPR‑Cas mediated insertion, followed by selection under antibiotic or metabolic pressure. Stable systems contribute approximately 55 % of the Algal Protein Expression System market value, reflecting their dominance in commercial biomanufacturing, especially for therapeutic enzymes, vaccine antigens, and high‑value nutraceuticals. Their long‑term productivity offsets higher upfront R&D costs, as scale‑up to industrial photobioreactors yields consistent titers and simplifies regulatory filings through defined genetic constructs. Recent improvements in chloroplast engineering have lifted expression levels to >5 g L⁻¹, narrowing the historical yield disparity with bacterial hosts. Nevertheless, stable platforms face challenges related to insertion site effects, gene silencing, and longer development timelines, which temper their market expansion. Within the market taxonomy, stable expression remains the principal growth engine, driven by demand for reproducible, GMP‑compliant protein supplies.
